
Global Inactivated Vaccine Market - Forecasts to 2027
According to a new market research report published by Global Market
Estimates, the Global Inactivated Vaccine Market is projected to grow at a CAGR value of 10.5% from
2022 to 2027.
Growing health consciousness and government efforts
to support vaccination, technological developments and infrastructure upgrades
in the healthcare system, increased emphasis on research studies, and
cooperation among various top research facilities in the domain to find a new
methodology to enhance inactivated vaccines are all contributing to the market
growth.
Browse 151 Market Data
Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Inactivated Vaccine
Market - Forecast to 2027" https://www.globalmarketestimates.com/market-report/inactivated-vaccine-market-3754
Key Market Insights
·
The viral vaccine segment is expected to be the fastest-growing segment in the Inactivated
Vaccine market from 2022 to 2027 as per the vaccine type outlook
·
The solvent detergent method segment is expected to
be the fastest-growing segment in the Inactivated Vaccine market from 2022 to
2027 as per the method of inactivation outlook
·
Based on route of administration, the subcutaneous segment
is expected to be the fastest-growing segment in the Inactivated Vaccine market
from 2022 to 2027
·
North America (the United States, Canada, and
Mexico) will have a dominant share in the Global Inactivated Vaccine market
from 2022 to 2027
·
GlaxoSmithKline plc, Merck & Co., Inc, CSL
Limited, Sanofi, Valneva SE, Bharat Biotech, Pfizer Inc., Bavarian Nordic,
Inovio Pharmaceuticals, Inc., Novavax, Inc., Serum Institute of India Pvt.Ltd.,
Daiichi Sankyo Company, Limited, Bavarian Nordic, Mitsubishi Tanabe Pharma
Corporation, among others are key players in the inactivated vaccines market.
Vaccine Type Outlook (Revenue, USD Billion,
2022 - 2027)
·
Viral Vaccine
· Bacterial Vaccine
Method of Inactivation Outlook (Revenue,
USD Billion, 2022 - 2027)
·
Detergent Method
·
Radiation Method
·
pH Concentration
·
Heat Inactivation
·
Others
Route of Administration Outlook (Revenue,
USD Billion, 2022 - 2027)
·
Oral
·
Subcutaneous
·
Intravenous
·
Others
Regional Outlook (Revenue, USD Billion, 2022-2027)
North America
- The
U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest
of Europe
Asia Pacific
- China
- India
- Japan
- South
Korea
- Australia
- Rest
of APAC
Central & South America
- Brazil
- Argentina
- Rest
of CSA
Middle East & Africa
- Saudi
Arabia
- UAE
- Rest
of MEA
Contact:
Yash Jain
Email
address: yash.jain@globalmarketestimates.com
Phone
Number: +16026667238